DOCSLIB.ORG

Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Product List 2015 WE LIVE SERVICE Certificates quartett owns two productions sites that are certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list 2015 quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. First of all we would like to introduce ourselves to you. Founded as a family-run company in 1986, quartett ensures for more than a quarter of a century consistent quality of products. Service and support of our valued customers are our daily businesses. And we will continue! In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 and a second one in 2011 supported this decision. The company specialized its product profile in the field of manufacturing synthetic peptides for antibody production, peptides such as protease inhibitors, biochemical reagents and products for histology, cytology and immunohistology. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals, and private doctor offices. But we are not only limited to provide our customers with consumable chemicals. Since quartett already offered cosmetic peptides, in 2011 we started working in the cosmetic field creating YOUmeDERM® care products. Service and quality are not only words for us. We have set ourself the task to provide you with the best quality solutions in all spheres of research. quartett owns two production sites that are certified according to EN ISO 9001:2008 & EN ISO 13485:2012 + AC:2012 and work in compliance with GMP conformity. Our quality management guarantees products of highest quality. Over the past decades we have steadily improved and enhanced our capabilities to satisfy your expectations. The new catalog 2015 gives an overview about our products we will offer from now on. This includes biochemicals, such as peptides and protease inhibitors, cosmetics, more than 8000 antibodies, detection systems as well as a wide variety of laboratory reagents for immunohistochemistry, histology and cytology. In addition to our range of products we offer services including custom synthesis of peptides, sugar amino acids, carbohydrates, nucleosides, as well as antibody production services. One of quartett‘s new services can be found in the field of cosmetics including development of new cosmetics according to your specifications. After 29 years it is again time to say thanks to each of our clients and business partners for trusting in us. Without them we were not as successful as we are and we are proud to have each of you in our quartett family. Welcome to quartett! Be part of us! 3 1. Antibodies 7 1.1. Antibodies for FFPE and Frozen Sections 7 NEW 1.2. Antibodies FITC-conjugated 197 2. Immunohistochemical Detection Systems 198 2.1. Streptavidin / Biotin Systems - ProTaqs® Essencial 199 2.2. Streptavidin / Biotin Systems - ProTaqs® Rapido 199 2.3. Polymer Systems - ProTaqs® Suprema PolyColor 200 2.4. Polymer Systems - ProTaqs® Suprema DoubleStain 202 NEW 2.5. Polymer Systems - ProTaqs® Suprema TripleStain 204 NEW 2.6. Single Components for Immunhistochemical Detection Systems 205 2.6.1. Streptavidin and Enzyme Complexes 205 2.6.2. Secondary Antibodies 205 2.6.3. Secondary Antibodies for Double Staining Detection Systems 206 2.6.4. Chromogens for Alkaline Phosphatase 206 2.6.5. Chromogens for Horseradish Peroxidase 206 2.6.6. Sera 207 3. Reagents for Immunohistochemistry / Histology / Cytology 208 3.1. Histological / Cytological Stains 208 3.1.1. Stain Solutions 208 3.1.2. Fast Stains 209 3.1.3. Special Stains 210 3.2. Buffer 211 3.2.1. Buffer Bags with Pre-mixed Salts 212 3.2.2. Citrate Buffer / Citrate EDTA Buffer / EDTA Buffer 212 3.2.3. Michel’s Buffer 213 3.2.4. Phosphate Buffered Saline / PBS 213 3.2.5. TRIS Buffered Saline / TBS 215 3.2.6. TRIS EDTA Buffer / TRIS EDTA Citrate Buffer 216 3.2.7. Chromogen Dilution Solutions 216 3.2.8. Buffer for Electrophoresis 217 3.3. Antigen Retrieval 218 3.4. Antibody Diluents 219 3.5. Blocking Reagents 220 3.6. Mounting Media 220 3.7. Fixatives 221 3.8. Decalcifier 222 3.9. Dehydration and Clearing Agents 222 3.10. Intermedium - Xylene Alternative ProTaqs® Clear 223 4. Instruments for Histology 225 4.1. Humidity Chamber - Slide Humidore 225 4.2. Tissue Float Bath 3 in 1 *** IVD *** 225 5. Molecularbiology and In-situ-Hybridization 227 5.1. Fluorescence-In-situ-Hybridization (FISH) 227 5.1.1. ProTaqs® jellyFISH Probes 228 NEW 5.1.2. Pretreatment and FISH on Paraffin Tissues jelly 231 NEW by FProISHTaqs® 5.2. Wash Solutions and Buffer 231 4 6. Microbiology 232 6.1. Microbiological Stains 232 6.2. FITC Stain Kits for Microbiology 232 6.3. Mounting Media 232 6.4. Buffer 233 7. Accessories for Anatomy and Pathology 234 8. Chemical Reference Standards 236 9. Peptides 237 9.1. Amino Acid Derivatives 237 9.2. Building Blocks 239 9.3. Enzyme Inhibitors 242 9.3.1. Protease Inhibitors 242 9.3.2. Protease Inhibitor Cocktail Kits 249 9.3.3. Protease and Phosphatase Inhibitor Cocktail Kits 250 NEW 9.4. Collagenase Inhibitors 251 10. Services 252 10.1. Peptide Services 252 10.1.1. Custom Peptide Synthesis 252 10.1.2. Modification and Derivatization of Peptides 253 10.1.3. Isolation and Purifcation of Peptides 253 10.1.4. Peptide Libraries 253 10.2. Sugar Amino Acids (SAAs) 254 10.3. Carbohydrates 254 10.4. Nucleosides 254 10.5. Custom Antibody Production Services 254 10.5.1. Polyclonal Antisera and Antibodies from Rabbit 254 10.5.2. Monoclonal Mouse Antibodies 255 10.5.3. Monoclonal Rabbit Antibodies 255 10.5.4. Modification of Mono- and Polyclonal Antibodies 255 11. Cosmetics 256 11.1. YOUmeDERM® Care Products 256 NEW 11.2. Cosmetics Services and Support 257 12. Conditions of Supply 258 12.1. Address 258 12.2. Orders 258 12.3. Shipments 258 12.4. Shipping Charges 258 12.5. Prices 258 12.6. Payment and Credit Terms 259 12.7. Returns and Cancellations 259 12.8. Limited Warranty 259 12.9. Breakages and Shortages 259 12.10. Reservation of Property Rights 259 12.11. Liabilities and Conditions 259 12.12. Applicable Law, Jurisdiction and Partial Invalidity 259 12.13. Technical Support 259 5 Explanations AP Alkaline Phosphatase Bov Bovine Ch Chicken Ct Cat Conc. Concentrate Cw Cow Dg Dog Du Duck EIA Enzymimmunoassay ELISA Enzyme-linked Immunosorbent Assay FACS Fluorescence-activated Cell Sorting FISH Fluorescence In-situ Hybridization Fs Fish Gp Guinea Pig Gt Goat HIER Heat Induced Epitope Retrieval Hm Hamster Hs Horse HRP Horseradish Peroxidase Hu Human IC or ICC Immunocytochemistry IF Immunofluorescence IH Immunohistology IHC(p,f) Immunohistochemistry (Paraffin, Frozen) IP Immunoprecipitation ISH In-Situ Hybridization LSAB Labeled Streptavidin / Biotin method mM Reacts w. most mammals Mk Monkey Ms Mouse Ov Ovine PIER Proteolytic Induced Epitope Retrieval Pg Pig Rb Rabbit RIA Radioimmunoassay Rt Rat RTU Ready-to-use Sam Salamander Sh Sheep WB Western Blot 6 1. Antibodies A 1.1. Antibodies for FFPE and Frozen Sections quartett offers more than 8000 antibodies for formalin fixed paraffin embedded and frozen sections. Please note that almost all antibodies are also available in other formats. In general we have: ▶ 100 µl concentrate ▶ 1 ml concentrate ▶ 3 ml ready-to-use ▶ 7 ml ready-to-use Just ask our customer service team for the correct order number, if you need another size than shown here. To all our previous trusted customers: As you will see quartett uses a new system of catalog numbers. Of course you can order as before using the well known catalog numbers and we will change it for you into the new number! Cat-No. Product Name Source Clone Application Reactivity Format Quantity 1-00001-07 14-3-3 epsilon Rb Polyclonal IHC(p,f), ELISA, IF, IP, WB Hu, Ms, Rb, Rt, ... Conc. 1 ml 1-00002-07 14-3-3 pan (alpha, beta, gamma, delta, epsilon) Rb Polyclonal IHC(p,f), IF, IP, WB Hu, Ms, Rt, ... Conc. 1 ml 1-00003-07 14-3-3 pan (alpha, beta, gamma, delta, epsilon) Rb Polyclonal IHC(p,f), ELISA, IF, IP, WB Hu, Ms, Rt, ... Conc. 1 ml 1-00004-07 14-3-3 zeta/delta Rb Polyclonal IHC(p,f), ELISA, IF, IP, WB Hu, Ms, Rb, Rt, ... Conc. 1 ml 1-00005-07 2-aminoethanethiol dioxygenase/ADO Rb Polyclonal IHC(p,f), IF, WB Hu, Ms, Rt, ... Conc. 1 ml 1-00006-07 2-oxoglutarate and iron dependent oxygenase Rb Polyclonal IHC(p,f), ELISA, IF, IP, WB Hu, Ms, Rb, Rt, ... Conc. 1 ml domain containing 1/OGFOD1 1-00007-07 2-oxoglutarate and iron dependent oxygenase Rb Polyclonal IHC(p,f), ELISA, IF, IP, WB Hu, Ms, Rt, ... Conc. 1 ml domain containing 2/OGFOD2 1-00008-07 2',3'-cyclic nucleotide 3' phosphodiesterase/CNP Rb Polyclonal IHC(p,f), ELISA, IF, IP, WB Hu, Ms, Rb, Rt, ... Conc. 1 ml 1-00009-07 2',5'-oligoadenylate synthetase 1/OAS1 Rb Polyclonal IHC(p,f), ELISA, IF, IP, WB Hu, Ms, ..
Recommended publications
  • Genotyping for Response to Physical Training

    Genotyping for Response to Physical Training

    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2019 Genotyping for Response to Physical Training Stacy Simmons Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Molecular Biology Commons Repository Citation Simmons, Stacy, "Genotyping for Response to Physical Training" (2019). Browse all Theses and Dissertations. 2109. https://corescholar.libraries.wright.edu/etd_all/2109 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. GENOTYPING FOR RESPONSE TO PHYSICAL TRAINING A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By STACY SIMMONS B.S., Wright State University, 2014 _________________________________________________________ 2019 Wright State University WRIGHT STATE UNIVERSITY GRADUATE SCHOOL July 29, 2019 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY Stacy Simmons ENTITLED Genotyping for Response to Physical Training BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science. ___________________________________ Michael Markey, Ph.D. Thesis Director ____________________________________ Madhavi P. Kadakia, Ph.D. Committee on Chair, Department of Biochemistry Final Examination and
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Recombinant Escheichia Coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate

    Recombinant Escheichia Coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate

    J. Ind. Eng. Chem., Vol. 12, No. 5, (2006) 757-761 Recombinant Escheichia coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate Sun-Gu Lee† and Byung-Gee Kim* Department of Chemical and Biochemical Engineering, Pusan National University, Busan 609-735, Korea *School of Chemical Engineering, and Institute of Molecular Biology and Genetics, Seoul National University, Seoul 151-742, Korea Received April 24, 2006; Accepted May 22, 2006 Abstract: A recombinant Escherichia coli overexpressing CMP-kinase was constructed and employed as a whole cell biocatalyst for the conversion of cytidine 5′-monophosphate to cytidine 5′-triphosphate. In the whole cell biocatalysis, recombinant CMP kinase catalyzed the conversion of CMP to CDP, and endogenous acetate kinase of the E. coli was utilized for the ATP regeneration as well as for the conversion of CDP to CTP. A conversion yield of ca. 88 % CTP was obtained when starting with 20 mM CMP, 1 mM ATP, and 80 mM acetyl phosphate based on the initial CMP concentration. Endogenous pyruvate kinase and poly- phosphate kinase were inefficient in the process. The CTP production system was applied to the production of CMP-NeuAc by additionally introducing the CMP-NeuAc synthetase gene into the recombinant E. coli. Keywords: CMP-kinase, whole cell biocatalysis, ATP regeneration, cytidine 5′-monophosphate Introduction employing enzymes [4]. They applied various enzymatic 1) methods and chemical methods and concluded that the As glycosyltransferase-catalyzed synthetic techniques enzymatic method based on adenylate kinase/pyruvate are becoming recognized as powerful methods for the kinase provided the most convenient route to CTP. In the preparation of biologically important oligosaccharides, process, CTP was generated efficiently from an inexpen- the development of cost-efficient production methods for sive substrate, CMP.
  • Figure S1. Representative Report Generated by the Ion Torrent System Server for Each of the KCC71 Panel Analysis and Pcafusion Analysis

    Figure S1. Representative Report Generated by the Ion Torrent System Server for Each of the KCC71 Panel Analysis and Pcafusion Analysis

    Figure S1. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. A Figure S1. Continued. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. B Figure S2. Comparative analysis of the variant frequency found by the KCC71 panel and calculated from publicly available cBioPortal datasets. For each of the 71 genes in the KCC71 panel, the frequency of variants was calculated as the variant number found in the examined cases. Datasets marked with different colors and sample numbers of prostate cancer are presented in the upper right. *Significantly high in the present study. Figure S3. Seven subnetworks extracted from each of seven public prostate cancer gene networks in TCNG (Table SVI). Blue dots represent genes that include initial seed genes (parent nodes), and parent‑child and child‑grandchild genes in the network. Graphical representation of node‑to‑node associations and subnetwork structures that differed among and were unique to each of the seven subnetworks. TCNG, The Cancer Network Galaxy. Figure S4. REVIGO tree map showing the predicted biological processes of prostate cancer in the Japanese. Each rectangle represents a biological function in terms of a Gene Ontology (GO) term, with the size adjusted to represent the P‑value of the GO term in the underlying GO term database.
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review

    TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review

    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
  • Datasheet BA3564-2 Anti-FES Antibody

    Datasheet BA3564-2 Anti-FES Antibody

    Product datasheet Anti-FES Antibody Catalog Number: BA3564-2 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-FES Antibody Gene Name FES Source Rabbit IgG Species Reactivity human,mouse,rat Tested Application WB Contents 500ug/ml antibody with PBS ，0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen A synthetic peptide corresponding to a sequence at the C-terminus of human FES(808-822aa STIYQELQSIRKRHR). Purification Immunogen affinity purified. Observed MW Dilution Ratios Western blot: 1:500-2000 Storage 12 months from date of receipt，-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information FES(feline sarcoma oncogene) is an enzyme that in humans is encoded by the FES gene, also known as Proto-oncogene tyrosine-protein kinase Fes/Fps, Feline sarcoma/Fujinami avian sarcoma oncogene homolog, Proto-oncogene c-Fes, Proto-oncogene c-Fps, p93c-fes c-fes/fps protein, FPS, Oncogene FES, feline sarcoma virus, FPS. This gene encodes the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. Non-onc intervening sequences were present in the human counterpart. The gene product has tyrosine-specific protein kinase activity and that activity is required for maintenance of°Cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia, but it is also involved in normal hematopoiesis. A truncated transcript has been identified that is generated utilizing a start site in one of the far downstream exons but a protein product associated with this transcript has not been identified.
  • Découverte D'une Nouvelle Famille De Protéine Kinases Bactériennes

    Découverte D'une Nouvelle Famille De Protéine Kinases Bactériennes

    Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis Hien-Anh Nguyen To cite this version: Hien-Anh Nguyen. Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis. Sciences agricoles. Université de Grenoble, 2012. Français. NNT : 2012GRENV017. tel-00721757 HAL Id: tel-00721757 https://tel.archives-ouvertes.fr/tel-00721757 Submitted on 30 Jul 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITÉ DE GRENOBLE Spécialité : Chimie-Biologie Arrêté ministériel : 7 août 2006 Présentée par Hien-Anh NGUYEN Thèse dirigée par le Dr. Jean-Michel JAULT préparée au sein de l’Institut de Biologie Structurale J.-P. Ebel, et du CEA de Grenoble dans l'École Doctorale Chimie et Sciences du Vivant Découverte d’une nouvelle famille de protéines kinases bactériennes : Mécanisme de fonctionnement et rôle cellulaire de YdiB, un représentant chez B. subtilis Thèse soutenue publiquement le 23 mai 2012 devant le jury composé de : Mme. Patricia DOUBLET Rapporteur Prof.
  • Cellular and Molecular Signatures in the Disease Tissue of Early

    Cellular and Molecular Signatures in the Disease Tissue of Early

    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
  • Two-Dimensional Isobutyl Acetate Production Pathways to Improve Carbon Yield

    Two-Dimensional Isobutyl Acetate Production Pathways to Improve Carbon Yield

    ARTICLE Received 23 Apr 2015 | Accepted 13 May 2015 | Published 25 Jun 2015 DOI: 10.1038/ncomms8488 OPEN Two-dimensional isobutyl acetate production pathways to improve carbon yield Yohei Tashiro1, Shuchi H. Desai1,2 & Shota Atsumi1,2 For an economically competitive biological process, achieving high carbon yield of a target chemical is crucial. In biochemical production, pyruvate and acetyl-CoA are primary building blocks. When sugar is used as the sole biosynthetic substrate, acetyl-CoA is commonly generated by pyruvate decarboxylation. However, pyruvate decarboxylation during acetyl-CoA formation limits the theoretical maximum carbon yield (TMCY) by releasing carbon, and in some cases also leads to redox imbalance. To avoid these problems, we describe here the construction of a metabolic pathway that simultaneously utilizes glucose and acetate. Acetate is utilized to produce acetyl-CoA without carbon loss or redox imbalance. We demonstrate the utility of this approach for isobutyl acetate (IBA) production, wherein IBA production with glucose and acetate achieves a higher carbon yield than with either sole carbon source. These results highlight the potential for this multiple carbon source approach to improve the TMCY and balance redox in biosynthetic pathways. 1 Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, California 95616, USA. 2 Microbiology Graduate Group, University of California, Davis, One Shields Avenue, Davis, California 95616, USA. Correspondence and requests for materials should be addressed to S.A. (email: [email protected]). NATURE COMMUNICATIONS | 6:7488 | DOI: 10.1038/ncomms8488 | www.nature.com/naturecommunications 1 & 2015 Macmillan Publishers Limited. All rights reserved. ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8488 iochemical production from biomass, a renewable resource OH synthesized from CO2 and sunlight, may contribute to a 1 Bcarbon-neutral society .
  • Acetate Activation in Methanosaeta Thermophila: Characterization of the Key Enzymes Pyrophosphatase and Acetyl-Coa Synthetase

    Acetate Activation in Methanosaeta Thermophila: Characterization of the Key Enzymes Pyrophosphatase and Acetyl-Coa Synthetase

    Hindawi Publishing Corporation Archaea Volume 2012, Article ID 315153, 10 pages doi:10.1155/2012/315153 Research Article Acetate Activation in Methanosaeta thermophila: Characterization of the Key Enzymes Pyrophosphatase and Acetyl-CoA Synthetase Stefanie Berger, Cornelia Welte, and Uwe Deppenmeier Institute for Microbiology and Biotechnology, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany Correspondence should be addressed to Uwe Deppenmeier, [email protected] Received 16 May 2012; Accepted 30 June 2012 Academic Editor: Francesca Paradisi Copyright © 2012 Stefanie Berger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The thermophilic methanogen Methanosaeta thermophila uses acetate as sole substrate for methanogenesis. It was proposed that the acetate activation reaction that is needed to feed acetate into the methanogenic pathway requires the hydrolysis of two ATP, whereas the acetate activation reaction in Methanosarcina sp. is known to require only one ATP. As these organisms live at the thermodynamic limit that sustains life, the acetate activation reaction in Mt. thermophila seems too costly and was thus reevaluated. It was found that of the putative acetate activation enzymes one gene encoding an AMP-forming acetyl-CoA synthetase was highly expressed. The corresponding enzyme was purified and characterized in detail. It catalyzed the ATP-dependent formation of acetyl- CoA, AMP, and pyrophosphate (PPi) and was only moderately inhibited by PPi. The breakdown of PPi was performed by a soluble pyrophosphatase. This enzyme was also purified and characterized. The pyrophosphatase hydrolyzed the major part of PPi (KM = 0.27 ± 0.05 mM) that was produced in the acetate activation reaction.
  • TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase

    TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase

    Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
  • DDX5 Targets Tissue-Specific Rnas to Promote Intestine Tumorigenesis

    DDX5 Targets Tissue-Specific Rnas to Promote Intestine Tumorigenesis

    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.25.006668; this version posted March 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. DDX5 targets tissue-specific RNAs to promote intestine tumorigenesis Nazia Abbasi1,4, Tianyun Long1,4, Yuxin Li1, Evelyn Ma1, Brian A. Yee1, Parth R. Patel1, Ibrahim M SayeD2, Nissi Varki2, Soumita Das2, PraDipta Ghosh1, 3, Gene W. Yeo1, WenDy J.M. Huang1,5 1 Department of Cellular anD Molecular MeDicine, University of California San Diego, La Jolla, CA 2 Department of Pathology, University of California San Diego, La Jolla, CA 3 Department of MeDicine, University of California San Diego, La Jolla, CA 4 These authors contributeD equally 5 CorresponDing author email: [email protected] Abstract Tumorigenesis in Different segments of the intestinal tract involves tissue-specific oncogenic Drivers. In the colon, complement component 3 (C3) activation is a major contributor to inflammation anD malignancies. By contrast, tumorigenesis in the small intestine involves fatty aciD-binding protein 1 (FABP1). However, little is known of the upstream mechanisms Driving their expressions in Different segments of the intestinal tract. Here, we report that an RNA binDing protein DDX5 augments C3 and FABP1 expressions post-transcriptionally to promote tumorigenesis in the colon anD small intestine, respectively. Mice with epithelial-specific knockout of DDX5 are protecteD from intestine tumorigenesis. The iDentification of DDX5 as the common upstream regulator of tissue-specific oncogenic molecules proviDes a new therapeutic target for intestine cancers.